Skip to main content
HR 1669 109th Congress House

Pharmacy Benefit Manager Transparency Act of 2005

Official title: To ensure integrity in the operation of pharmacy benefit managers.

Introduced: December 8, 2005 See on congress.gov
Law Business recordsCommerceConsumer discountsConsumer education
More subjectsShow fewer subjects
Consumer protectionContractsDrug industryDrug utilizationDrugsFeesFinance and Financial SectorFinancial statementsFines (Penalties)Generic drugsGovernment Operations and PoliticsGovernment paperworkHealthHealth care fraudHealth insuranceInsurance companiesMedical statisticsPatients' rightsPharmaciesPrescription pricingRestrictive trade practices
Sign in to write a letter Sign in to watch
This bill died when the 109th Congress ended
It never became law before the 109th Congress (2005–2006) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 13, 2005
Referred to the Subcommittee on Health.
Apr 14, 2005
Referred to the House Committee on Energy and Commerce.
Apr 14, 2005
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action May 13, 2005

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Pharmacy Benefit Manager Transparency Act of 2005 - Prohibits any pharmaceutical drug manufacturer from having a controlling interest in an entity that is a pharmacy benefit manager. Allows the Secretary of Health and Human Services to issue civil penalties for violations as necessary.

Prohibits pharmacy benefit managers from making drug interchanges: (1) to a drug with a greater cost; (2) without disclosure to the individual of the savings associated with the interchange; or (3) from a drug with generic equivalents to a drug without generic equivalents, unless the latter is lower in cost than each of the generic equivalents of the drug from which the prescription would be changed.

Requires pharmacy benefit managers to annually disclose all compensation received from drug manufacturers to the Antitrust Division of the Department of Justice (DOJ) and to the client plans of such manager.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 2
All 2 Republican 2
R
Boozman, John
Arkansas · Dec 8, 2005
 R
Moran, Jerry
Kansas · Apr 14, 2005
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1669: Pharmacy Benefit Manager Transparency Act of 2005. 109th Congress. Open America. https://openamerica.io/bill/109-HR-1669/
MLA
"H.R. 1669: Pharmacy Benefit Manager Transparency Act of 2005." 109th Congress, 2026, Open America, https://openamerica.io/bill/109-HR-1669/.
Bluebook (legal)
H.R. 1669, 109th Cong. (2026), https://openamerica.io/bill/109-HR-1669/.
Markdown link
[H.R. 1669: Pharmacy Benefit Manager Transparency Act of 2005](https://openamerica.io/bill/109-HR-1669/)
Report a problem